A CAR T-cell therapy cleared disease-causing autoantibodies from the bloodstream of eight SLE patients without compromising vaccine response.| Lupus News Today
The FDA has granted fast track status to ADI-001, Adicet Bio’s CAR T-cell therapy for treatment-resistant systemic lupus erythematosus (SLE).| Lupus News Today
Kite Pharma has initiated a global Phase 3 trial to test the CAR T-cell therapy anito-cel in relapsed or refractory multiple myeloma.| Rare Cancer News
Based on a clinical trial, the CAR T-cell therapy was approved for relapsed or refractory precursor B-cell acute lymphoblastic leukemia.| Rare Cancer News
Ovarian cancer tumors' microenvironment was seen to actively suppress the anti-cancer work of immune T-cells by blocking their energy supply.| Rare Cancer News
The FDA granted regenerative medicine advanced therapy status to the CAR T-cell therapy P-BCMA-ALLO1 for hard-to-treat multiple myeloma.| Rare Cancer News
CAR T-cells are able to rapidly eliminate disease-driving immune cells in people with neuromyelitis optica spectrum disorder, or NMOSD.| Neuromyelitis News
An open-label, multicenter Phase 2 clinical trial will test KYV-101 in people with refractory MG and positive for self-reactive antibodies.| Myasthenia Gravis News
The CAR T-cell therapy Carvykti controlled disease activity in most myeloma patients who hadn't fully responded to standard cell transplant.| Myeloma Research News
Seattle Children's will start a clinical trial testing CAR T-cell therapy in children with lupus this summer after getting FDA clearance.| Lupus News Today
The first patient has been treated in a Phase 1 clinical trial testing CAR T-cell therapy CC-97540 in people with severe, refractory lupus.| Lupus News Today